Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis. - Wikidata - wikimedia - TriplyDB

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis.

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis.

http://www.wikidata.org/entity/Q33785053

about

The efficacy of a pseudo-ceramide and eucalyptus extract containing lotion on dry scalp skin.Emollient treatment of atopic dermatitis: latest evidence and clinical considerations.

P2860

Q55002923-22F4CB62-7597-41C4-9E86-526C10CB42F7 Q55074071-27FEE5F4-98F1-43CC-97F2-5BE4693B6559

P2860

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis.

http://www.wikidata.org/entity/Q33785053

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@ast

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@en

type

label

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@ast

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@en

prefLabel

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@ast

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@en

P1433

Q33785053-19A564F4-6381-4B24-A803-2378B0FE3BD5

P1476

Q33785053-7C6AD9FE-C58B-4E7D-8B6C-AD3C0F94289A

P2093

Q33785053-0098DE44-4128-4227-8415-41CFAE084CF6

Q33785053-7613A697-ECE7-47D8-A8F1-95866C7032FB

Q33785053-7C09C9B9-B14F-4752-930B-FDD296EE5FDE

Q33785053-898D3346-569F-4127-A2B3-17E1B9D75222

Q33785053-919E324C-06CA-4ED2-90A1-B9C4AC628FED

Q33785053-95935895-84A4-4067-ACF2-03F75AC4AF5F

Q33785053-DE8B49E9-515E-4528-B9A3-03D6AE554E28

P2860

Q33785053-0252887E-DC0A-4820-8AB8-0E17D21BE746

Q33785053-05BF0945-7552-4070-A9FF-FEBF10BE5723

Q33785053-062F1183-E908-4AF4-9287-E9D132DD71D9

Q33785053-1990416F-2EBA-4096-A624-45A1FE733872

Q33785053-1EA7D373-7F4E-46B1-916E-C1C1341D0744

Q33785053-35AFE324-1174-4B7C-A8B1-4304F0F84E21

Q33785053-3CFE5FAC-B39C-4896-936C-514F0489794F

Q33785053-3D95874B-E762-4BC5-AB49-A0AA008A3EEA

Q33785053-43507F89-705C-4F3B-885C-A7A4FF1BC68D

Q33785053-437D9BAB-E5E7-40DA-B109-A1A6AEB6BC90

P2888

Q33785053-548D3435-DA4B-4BE0-AF65-F0BA2DBEA8EB

P304

Q33785053-02BD08B6-BFF4-40B9-9C4D-EC839EF37DE7

P31

Q33785053-39FA054F-619B-4D58-978B-2CC07E5BAB96

P356

Q33785053-BABA96F5-051B-4B38-A31B-F72DDE6D6B0A

P433

Q33785053-82C8CF76-5560-4019-BA56-C8381E10916F

P478

Q33785053-57A04347-D5BF-413F-A282-D3067735FBC9

P577

Q33785053-80499256-E73C-4CC9-89A2-937779E88F69

P5875

Q33785053-08B457EA-A9CA-4F06-8744-987B1BF6715E

P6179

Q33785053-A7D0286A-A2F2-419A-A922-4A08E2E2C7F0

P698

Q33785053-5B5A3C97-43D3-4DE9-A9E8-2FCB892E366F

P932

Q33785053-143C8995-079D-4459-AEFB-6F97103ECB13

P356

S13555-014-0048-Z

P1433

Dermatology and therapy

P1476

Evaluation of a Pseudoceramide ...... to-Moderate Atopic Dermatitis.

@en

P2093

Amelie Clementine Seghers

http://www.w3.org/2001/XMLSchema#string

Carina Marie Grönhagen

http://www.w3.org/2001/XMLSchema#string

Lucinda Tan

http://www.w3.org/2001/XMLSchema#string

Madeleine Sheun Ling Ho

http://www.w3.org/2001/XMLSchema#string

Mark Boon Yang Tang

http://www.w3.org/2001/XMLSchema#string

Sophie Chan Cai

http://www.w3.org/2001/XMLSchema#string

Yoke Chin Giam

http://www.w3.org/2001/XMLSchema#string

P2860

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis

Testing for irritation with a multifactorial approach: comparison of eight non-invasive measuring techniques on five different irritation types.

The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.

Eczema and ceramides: an update.

Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?

Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients

On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides

Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.

Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score.

Lipids and skin barrier function--a clinical perspective.

P2888

s13555-014-0048-z

P304

83-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13555-014-0048-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260718648

http://www.w3.org/2001/XMLSchema#string

P6179

1024455552

http://www.w3.org/2001/XMLSchema#string

P698

24619816

http://www.w3.org/2001/XMLSchema#string

P932

4065272

http://www.w3.org/2001/XMLSchema#string